NASDAQ:VTGN
Vistagen Therapeutics, Inc.
Vistagen Therapeutics, Inc.'s revenue grew 161.1% in fiscal 2026 to $1.3M while operating margin rose to −5683.7%. The diluted share count rose 23.3%.Summary generated from Vistagen Therapeutics, Inc.'s SEC filings. Latest annual report filed Jun 15, 2026.
Key statistics
Fiscal 2026 from SEC filings. MethodologyRevenue (FY26)$1.3M
Revenue growth+161.1%
Revenue, 5-yr CAGR+3.1%
Gross marginn/a
Operating margin−5683.7%
Net margin−5491.3%
ROICn/a
Return on equity−131.6%
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+23.3%
Financials
| Item | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Revenue | 1 | −0 | 1 | 0 | 1 |
| Operating income | −48 | −59 | −33 | −56 | −72 |
| Net income | −48 | −59 | −29 | −51 | −70 |
| Free cash flow | −45 | −50 | −26 | n/a | n/a |
Recent filings
- 8-KDirector or officer change
Oct 9, 2026 - 8-KRegulation FD disclosure
Sep 25, 2026 - 8-KOther events
Sep 24, 2026 - 8-KOther events
Sep 22, 2026 - 8-KResults of a shareholder vote
Sep 11, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 14, 2026 - 8-KResults of operations and financial condition
Aug 14, 2026 - 8-KRegulation FD disclosure
Aug 6, 2026